There have been quite a few successful published programmes for pancreatic surgery as well as published ERAS guidelines. But less is known about the economic benefits of these programmes.
What this paper adds:
This was a Canadian retrospective cost minimization analysis of patients undergoing pancreaticoduodenectomy with an ERAS programme versus standard care. Despite only a small reduction in total length of stay (10 vs 11 days, p=0.003), there was a pretty impressive cost saving of over 13,000 Canadian dollars per patient (including readmissions, $16,627 vs $29,872, p=0.016). The main areas of cost savings were through reducing unnecessary laboratory tests and imaging investigations. Showing nicely that it is not just reducing bed-days that saves money.
Enhanced Recovery After Surgery in Octogenarians undergoing hepatopancreatobiliary surgery Jordan N Robinson, Joshua M K Davis, Ryan C Pickens, Allyson R Cochran, Lacey King, Patrick Salibi,, David A Iannitti,…